A phase 1 dose-escalation and expansion-cohort study of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients (pts) with advanced solid tumors

被引：0
|
作者：
Shapiro, Geoffrey
Barve, Minal A.
Bhave, Manali A.
Subbiah, Vivek
Uttamsingh, Shailaja
Sharma, Keerti
Andrianova, Lana
Patnaik, Amita
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Mary Crowley Canc Res, Dallas, TX USA
[3] Emory Univ, Sch Med, Atlanta, GA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA
[5] Exelixis Inc, Alameda, CA USA
[6] START, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3176
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase 1 Study of the Oral CDK7 Inhibitor XL102 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors (QUARTZ-101): Initial Results From the Dose-Escalation Stage
    Patnaik, Amita
    Barve, Minal
    Bhave, Manali
    Subbiah, Vivek
    Rasco, Drew
    Bhatt, Aarohi
    Li, Jing
    Andrianova, Svetlana
    Shapiro, Geoffrey
    CANCER RESEARCH, 2023, 83 (05)
  • [2] First in human phase 1 dose escalation and expansion study of the safety and pharmacokinetics of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients with inoperable locally advanced or metastatic solid tumors, including breast cancer
    Patnaik, Amita
    Barve, Minal
    Bhave, Manali
    Subbiah, Vivek
    Atwal, Sumandeep
    Sharma, Keerti
    Scheffold, Christian
    Wetmore, Cynthia
    Shapiro, Geoffrey
    CANCER RESEARCH, 2022, 82 (04)
  • [3] Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors
    Nishikawa, Tadaaki
    Matsumoto, Koji
    Tamura, Kenji
    Yoshida, Hiroyuki
    Imai, Yuichi
    Miyasaka, Aki
    Onoe, Takuma
    Yamaguchi, Satoshi
    Shimizu, Chikako
    Yonemori, Kan
    Shimoi, Tatsunori
    Yunokawa, Mayu
    Xiong, Hao
    Nuthalapati, Silpa
    Hashiba, Hideyuki
    Kiriyama, Tsukasa
    Leahy, Terri
    Komarnitsky, Philip
    Fujiwara, Keiichi
    CANCER SCIENCE, 2017, 108 (09) : 1834 - 1842
  • [4] Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors
    Shapiro, Geoffrey I.
    Do, Khanh T.
    Tolaney, Sara M.
    Hilton, John F.
    Cleary, James M.
    Wolanski, Andrew
    Beardslee, Brian
    Hassinger, Faith
    Bhushan, Ketki
    Cai, Dongpo
    Downey, Elizabeth
    Pruitt-Thompson, Solida
    Barry, Suzanne M.
    Kochupurakkal, Bose
    Geradts, Joseph
    Unitt, Christine
    D'Andrea, Alan D.
    Muzikansky, Alona
    Piekarz, Richard
    Doyle, L. Austin
    Supko, Jeffrey
    CANCER RESEARCH, 2017, 77
  • [5] Phase I, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of single-agent PF-03758309, an oral PAK inhibitor, in patients with advanced solid tumors.
    Mileshkin, L. R.
    Rosen, L. S.
    Blumenkopf, T.
    Breazna, A.
    Darang, S.
    Davison, J.
    Gallo, J.
    Goldman, J. W.
    Wang, D. D.
    Zhang, S.
    Eckhardt, S. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] A phase I dose-escalation and expansion study of intratumoral CV8102 as single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors.
    Eigentler, Thomas
    Bauernfeind, Franz G.
    Becker, Jurgen C.
    Brossart, Peter
    Fluck, Michael
    Heinzerling, Lucie
    Krauss, Jurgen
    Mohr, Peter
    Ochsenreither, Sebastian
    Schreiber, Jutta Sylvina
    Terheyden, Patrick
    Weide, Benjamin
    Weishaupt, Carsten
    Funkner, Fatma
    Muth, Anke
    Kays, Sarah-Katharina
    Stosnach, Claudia
    Daehling, Angelika
    Quintini, Gianluca
    Gnad-Vogt, Senta Ulrike
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumors.
    Tolcher, Anthony
    Mamdani, Hirva
    Chalasani, Pavani
    Meric-Bernstam, Funda
    Gazdoiu, Mihaela
    Makris, Lukas
    Pultar, Philippe
    Voliotis, Dimitris
    CANCER RESEARCH, 2021, 81 (13)
  • [8] A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors
    Deutsch, Eric
    Moyal, Elizabeth Cohen-Jonathan
    Gregorc, Vanesa
    Zucali, Paolo Andrea
    Menard, Jean
    Soria, Jean-Charles
    Kloos, Ioana
    Hsu, Jeff
    Luan, Ying
    Liu, Emily
    Vezan, Remus
    Graef, Thorsten
    Rivera, Sofia
    ONCOTARGET, 2017, 8 (34) : 56199 - 56209
  • [9] Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies
    Salgia, Ravi
    Patel, Premal
    Bothos, John
    Yu, Wei
    Eppler, Steve
    Hegde, Priti
    Bai, Shuang
    Kaur, Surinder
    Nijem, Ihsan
    Catenacci, Daniel V. T.
    Peterson, Amy
    Ratain, Mark J.
    Polite, Blase
    Mehnert, Janice M.
    Moss, Rebecca A.
    CLINICAL CANCER RESEARCH, 2014, 20 (06) : 1666 - 1675
  • [10] A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
    Harding, James J.
    Telli, Melinda
    Munster, Pamela
    Voss, Martin H.
    Infante, Jeffrey R.
    DeMichele, Angela
    Dunphy, Mark
    Le, Mai H.
    Molineaux, Chris
    Orford, Keith
    Parlati, Frank
    Whiting, Sam H.
    Bennett, Mark K.
    Tannir, Nizar M.
    Meric-Bernstam, Funda
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4994 - 5003
12345